The global modification of mammalian and plasmid DNAs by the novel platinum compounds cis-[PtCl(2)(isopropylamine)(1-methylimidazole)] and trans-[PtCl(2)(isopropylamine)(1-methylimidazole)] and the reactivity of these compounds with reduced glutathione (GSH) were investigated in cell-free media using various biochemical and biophysical methods. Earlier cytotoxicity studies had revealed that the replacement of the NH(3) groups in cisplatin by the azole and isopropylamine ligands lowers the activity of cisplatin in both sensitive and resistant cell lines. The results of the present work show that this replacement does not considerably affect the DNA modifications by this drug, recognition of these modifications by HMGB1 protein, their repair, and reactivity of the platinum complex with GSH. These results were interpreted to mean that the reduced activity of this analog of cisplatin in tumor cell lines is due to factors that do not operate at the level of the target DNA. In contrast, earlier studies had shown that the replacement of the NH(3) groups in the clinically ineffective trans isomer (transplatin) by the azole and isopropylamine ligands results in a radical enhancement of its activity in tumor cell lines. Importantly, this replacement also markedly alters the DNA binding mode of transplatin, which is distinctly different from that of cisplatin, but does not affect reactivity with GSH. Hence, the results of the present work are consistent with the view and support the hypothesis systematically tested by us and others that platinum drugs that bind to DNA in a fundamentally different manner from that of conventional cisplatin may have altered pharmacological properties.

Institute of Biophysics Academy of Sciences of the Czech Republic v v i Kralovopolska 135 61265 Brno Czech Republic

Zobrazit více v PubMed

Cancer Res. 1992 Sep 15;52(18):5065-72 PubMed

Prog Nucleic Acid Res Mol Biol. 2001;67:93-130 PubMed

Biophys Chem. 1996 Jun 11;60(3):135-42 PubMed

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5345-9 PubMed

Nature. 1999 Jun 17;399(6737):708-12 PubMed

Drug Resist Updat. 2005 Jun;8(3):131-46 PubMed

Eur J Biochem. 1997 Jun 1;246(2):508-17 PubMed

Biochemistry. 1985 Jan 29;24(3):707-13 PubMed

Anticancer Agents Med Chem. 2007 Jan;7(1):111-23 PubMed

Mol Pharmacol. 2006 Nov;70(5):1708-19 PubMed

FEBS Lett. 1994 May 16;344(2-3):201-6 PubMed

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982-5 PubMed

Carcinogenesis. 1989 Dec;10(12):2367-9 PubMed

Prog Nucleic Acid Res Mol Biol. 2002;71:1-68 PubMed

Biophys Chem. 1990 Apr;35(2-3):129-41 PubMed

Biochemistry. 1996 Mar 5;35(9):2992-3000 PubMed

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20743-8 PubMed

Mutat Res. 2001 Jul 1;478(1-2):1-21 PubMed

Science. 1992 Apr 10;256(5054):234-7 PubMed

Pharmacol Ther. 1987;34(2):155-66 PubMed

Drug Metab Dispos. 2003 Jul;31(7):916-23 PubMed

Cancer Res. 1999 Aug 15;59(16):3968-71 PubMed

Proc Natl Acad Sci U S A. 1980 Jul;77(7):3855-9 PubMed

Science. 1979 Mar 9;203(4384):1014-6 PubMed

Nucleic Acids Res. 1985 Apr 25;13(8):2881-95 PubMed

Biochemistry. 1987 Jun 16;26(12):3303-7 PubMed

J Inorg Biochem. 2006 Dec;100(12):1955-64 PubMed

Biochemistry. 2003 May 27;42(20):6321-32 PubMed

Anticancer Drug Des. 1986 Apr;1(2):95-109 PubMed

J Biol Inorg Chem. 2005 Nov;10(7):722-31 PubMed

Anticancer Agents Med Chem. 2007 Jan;7(1):19-34 PubMed

J Med Chem. 2006 Apr 20;49(8):2640-51 PubMed

Chem Rev. 1999 Sep 8;99(9):2499-510 PubMed

J Biol Chem. 2002 Dec 13;277(50):48076-86 PubMed

Drug Resist Updat. 1998;1(4):243-54 PubMed

J Biol Chem. 1992 Jul 5;267(19):13520-7 PubMed

Drug Resist Updat. 2002 Jul-Aug;5(3-4):147-61 PubMed

Crit Rev Oncol Hematol. 2000 Aug;35(2):109-20 PubMed